Aethlon Medical Faces Nasdaq Delisting After Failing Minimum Bid Price Requirement

Reuters
Oct 23
Aethlon Medical Faces Nasdaq Delisting After Failing Minimum Bid Price Requirement

Aethlon Medical Inc. has announced that it received a notice from the Nasdaq Stock Market stating the company is not in compliance with the minimum bid price requirement, as its common stock closed below $1.00 per share for 30 consecutive business days. To address this, Aethlon has implemented a 1-for-10 reverse stock split, effective October 16, 2025, with trading under the new structure beginning October 20, 2025. The company has requested a hearing before the Nasdaq Hearings Panel, which will temporarily prevent any immediate suspension or delisting actions, and its shares will continue to trade under the symbol "AEMD" while it seeks to regain compliance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-25-007719), on October 22, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10